.Attributes Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin resulted in improved progression-free and total survival, leading to FDA commendation as well as a brand-new treatment possibility for people.